Charles River Laboratories International (NYSE:CRL) Sets New 12-Month High – Here’s What Happened

Charles River Laboratories International, Inc. (NYSE:CRL)’s stock price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $335.72 and last traded at $338.57, with a volume of 540,666 shares trading hands. The stock had previously closed at $315.45.

Analyst Ratings Changes

A number of research firms have commented on CRL. Weiss Ratings restated a “sell (d-)” rating on shares of Charles River Laboratories International in a research note on Monday, September 28th. CLSA downgraded shares of Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a report on Monday, July 20th. Sanford C. Bernstein set a $250.00 price target on shares of Charles River Laboratories International in a research report on Wednesday, July 1st. Morgan Stanley increased their price objective on shares of Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a research note on Monday, October 12th. Finally, Zacks Research upgraded shares of Charles River Laboratories International from a “hold” rating to a “strong-buy” rating in a research report on Friday, October 2nd. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $302.33.

Charles River Laboratories International Stock Performance

The firm has a market capitalization of $16.26 billion, a PE ratio of -70.24, a price-to-earnings-growth ratio of 3.22 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The business’s fifty day simple moving average is $293.05 and its 200-day simple moving average is $232.43.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping the consensus estimate of $2.77 by $0.25. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. During the same quarter in the previous year, the firm earned $3.12 earnings per share. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities research analysts expect that Charles River Laboratories International, Inc. will post 11.38 EPS for the current year.

Insider Buying and Selling

In other Charles River Laboratories International news, EVP Victoria Creamer sold 4,179 shares of the stock in a transaction dated Thursday, August 6th. The shares were sold at an average price of $259.16, for a total transaction of $1,083,029.64. Following the completion of the transaction, the executive vice president owned 30,051 shares of the company’s stock, valued at $7,788,017.16. This represents a 12.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Birgit Girshick sold 6,500 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.90, for a total value of $1,819,350.00. Following the transaction, the chief executive officer owned 36,013 shares of the company’s stock, valued at approximately $10,080,038.70. The trade was a 15.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 91,971 shares of company stock worth $26,033,968 in the last 90 days. 1.30% of the stock is owned by company insiders.

Institutional Investors Weigh In On Charles River Laboratories International

Hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP grew its holdings in Charles River Laboratories International by 14.6% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock valued at $285,001,000 after buying an additional 210,260 shares in the last quarter. Bank of America Corp DE raised its holdings in shares of Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock worth $195,792,000 after acquiring an additional 54,500 shares in the last quarter. Amundi boosted its position in shares of Charles River Laboratories International by 175.2% during the 1st quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after acquiring an additional 492,301 shares during the last quarter. Van Berkom & Associates Inc. boosted its position in shares of Charles River Laboratories International by 11.2% during the 1st quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after acquiring an additional 50,462 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Charles River Laboratories International by 2.9% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 225,314 shares of the medical research company’s stock valued at $51,099,000 after acquiring an additional 6,401 shares during the last quarter. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a contract research and laboratory services company that supports pharmaceutical, biotechnology, medical device and academic research organizations. The company provides products and services used throughout the drug-development process, from early discovery and research through preclinical testing and manufacturing support.

Its offerings include research models, laboratory animal management, discovery and safety assessment services, toxicology testing, bioanalysis, and support for biologic, cell and gene therapy programs.